Analysis of epidermal growth factor receptor (EGFR) status in endometrial stromal sarcoma

Purpose: Endometrial stromal sarcomas (ESSs) are rare neoplasms, which are currently treated by surgery, whereas effective adjuvant therapies have not yet been established. Recently, epidermal growth factor receptor (EGFR) expression has been described in ESS, and a potential role of EGFR-targeted adjuvant therapies has been proposed. The aim of this study was to analyze EGFR status in an ESS series and to evaluate their potential role as molecular targets. Materials and Methods: EGFR status was investigated in a total of ten cases of ESS, which included seven low-grade ESS and three undifferentiated ESS cases. EGFR expression levels were assessed by immunohistochemistry, and gene amplification analysis was performed with dual-color fluorescence in situ hybridization (FISH). Results: Nine out of ten ESS cases showed positive immunostaining, whereas FISH analysis demonstrated constantly negative results. Conclusions: This study confirmed that EGFR is frequently overexpressed in ESS. FISH analysis did not show EGFR amplification in any of the tumors, therefore EGFR expression in ESS should be related to different genetic mechanisms.

EGFR; Endometrial Stromal Sarcoma (ESS); Immunohistochemistry; FISH

[1] Kurihara S., Oda Y., Ohishi Y., Iwasa A., Takahira T., Kaneki E. et al.: “Endometrial stromal sarcomas and related high-grade sarcomas: immunohistochemical and molecular genetic study of 31 cases”. Am. J. Surg. Pathol., 2008, 32, 1228.

[2] Hendrickson M.R., Tavassoli F.A., Kempson R.L., McCluggage W.G., Haller U., Kubik-Huch R.A.: “Mesenchymal Tumors and Related Lesions In: World Health Organisation Classification of Tumors. Pathology and Genetics of Tumors of the Breast and Female Genital Organs”. Tavassoli F.A., Devilee P. (eds.). Lyon: IARC Press, 2003, 233.

[3] Moinfar F., Azodi M., Tavassoli F.A.: “Uterine sarcomas”. Pathology 2007, 39, 55.

[4] Vera A.A., Guadarrama M.B.: “Endometrial stromal sarcoma: clinicopathological and immunophenotype study of 18 cases”. Ann. Diagn. Pathol., 2011, 15, 312.

[5] Nam J.H., Park J.Y.: “Update on treatment of uterine sarcoma”. Curr. Opin. Obstet. Gynecol., 2010, 22, 36.

[6] Seddon B.M., Davda R.: “Uterine sarcomas-recent progress and future challenges”. Eur. J. Radiol., 2011, 78, 30.

[7] Valduvieco I., Rovirosa A., Colomo L., De San Juan A., Pahisa J., Biete A.: “Endometrial stromal sarcoma. Is there a place for radiotherapy?”. Clin. Transl. Oncol., 2010, 12, 226.

[8] Dupont N.C., Disaia P.J.: “Recurrent endometrial stromal sarcoma: treatment with a progestin and gonadotropin releasing hormone agonist”. Sarcoma 2010, 353679, Epub 2010 Jun 10.

[9] Nakayama K., Ishikawa M., Nagai Y., Yaegashi N., Aoki Y., Miyazaki K.: “Prolonged long-term survival of low-grade endometrial stromal sarcoma patients with lung metastasis following treatment with medroxyprogesterone acetate”. Int. J. Clin. Oncol., 2010, 15, 179.

[10] De Miglio M.R., Mura A., Uras M.G., Manca A., Contini M., Murgia L. et al.: “High sensitivity of reverse-hybridization methodology in the detection of KRAS mutations from formalinfixed paraffin-embedded colorectal cancer samples”. Diagn. Mol. Pathol., 2010, 19, 201.

[11] Cossu-Rocca P., Zhang S., Roth L.M., Eble J.N., Zheng W., Karim F.W. et al.: “Chromosome 12p abnormalities in dysgerminoma of the ovary: a FISH analysis”. Mod. Pathol., 2006, 19, 611.

[12] Moinfar F., Gogg-Kamerer M., Sommersacher A., Regitnig P., Man Y.G., Zatloukal K. et al.: “Endometrial stromal sarcomas frequently express epidermal growth factor receptor (EGFR, HER-1): potential basis for a new therapeutic approach”. Am. J. Surg. Pathol., 2005, 29, 485.

[13] Mitsuhashi T., Nakayama M., Sakurai S., Fujimura M., Shimizu Y., Ban S. et al.: “KIT-negative undifferentiated endometrial sarcoma with the amplified epidermal growth factor receptor gene showing a temporary response to imatinib mesylate”. Ann. Diagn. Pathol., 2007, 11, 49.

[14] Cheng X., Yang G., Schmeler K.M., Coleman R.L., Tu X., Liu J. et al.: “Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy”. Gynecol. Oncol., 2011, 121, 323.

[15] Zandi R., Larsen A.B., Andersen P., Stockhausen M.T., Poulsen H.S.: “Mechanisms for oncogenic activation of the epidermal growth factor receptor”. Cell. Signal. 2007, 19, 2013.

[16] Bache K.G., Slagsvold T., Stenmark H.: “Defective downregulation of receptor tyrosine kinases in cancer”. EMBO J., 2004, 23, 2707.

[17] Sharma S.V., Bell D.W., Settleman J., Haber D.A.: “Epidermal growth factor receptor mutations in lung cancer”. Nat. Rev. Cancer, 2007, 7, 169.